Head and neck squamous cell carcinoma (HNSCC), including oral cancer, is the sixth most common malignancy in humans. Despite tremendous improvements in surgery, radiotherapy, and chemotherapy over the past decade, the prognosis for patients with HNSCCs has more or less remained unchanged for the past 30 years ([@bib14]; [@bib36]). This is primarily because patients continue to die from metastatic disease at regional and distant sites, although local recurrence and second primary tumours are also a cause of death in these patients. It is widely accepted that the presence of metastasis in cervical lymph nodes is a reliable prognostic indicator of survival and disease recurrence ([@bib20]; [@bib32]; [@bib37]; [@bib15]). In addition to nodal metastasis, extracapsular spread (ECS) of lymph node metastasis is significantly associated with a further increase in loco-regional recurrence and distant metastasis, further reducing the overall survival (OS) rate of patients with this disease ([@bib27]; [@bib28]; [@bib25]; [@bib16]; [@bib43]; [@bib42]; [@bib21]). The presence of ECS is therefore a marker for biologically aggressive disease, and is the most pivotal predictor of survival, recurrence, and distant metastasis. Thus, patients who present with ECS require intensification of multimodality therapy. However, the detection of ECS is currently performed by histological examination of the dissected lymph nodes after surgery, making it impracticable to determine ECS of lymph node metastasis preoperatively. Therefore, to determine patients with ECS, who would benefit from invasive treatment, it is necessary to determine the predictive markers that indicate a high risk of ECS.

Although ECS is frequently present in patients with advanced nodal metastasis, it is also detected not only in a small number of patients with early-nodal disease and but also even in those with a clinically negative (N0) neck ([@bib1]; [@bib10]). This has made prediction of ECS even more difficult. Improvements in various imaging modalities, such as computed tomography, magnetic resonance imaging, ultrasound, and positron emission tomography have allowed us to detect lymph node metastasis and ECS preoperatively. However, all these imaging methods are limited in their ability to detect smaller tumour volume ([@bib31]). The incidence of micrometastases that cannot be detected by any imaging technique is as high as 25%, and thus, on the basis of imaging criteria alone, it is still difficult to detect ECS occurring in early-nodal disease or N0 neck ([@bib12]).

New diagnostic strategies for the prediction of ECS are therefore urgently required to identify patients with aggressive disease. Identification of predictive biomarkers that indicate a high risk of ECS would have a major role in determining the optimal therapeutic strategy for these aggressive diseases and in achieving a high survival rate. Unfortunately, however, there are currently no molecular markers for the detection of ECS in oral squamous cell carcinomas (OSCCs).

The cyclin D1 gene (*CCND1*) is a proto-oncogene, located on chromosome 11q13, that is elevated in response to extracellular mitogens. It is also a rate-limiting regulator of G1-phase progression through the cell cycle, and has been shown to be associated with an increase in lymph node stage in anterior tongue cancer ([@bib24]; [@bib34]; [@bib6]; [@bib7]). Since 1998, we have been investigating alterations in *CCND1* using fluorescence *in situ* hybridisation (FISH), with fine-needle aspiration (FNA) biopsy samples from primary OSCCs, and have demonstrated clearly that *CCND1* numerical aberrations are significantly associated with an invasive phenotype and cervical lymph node metastasis in OSCCs ([@bib23], [@bib22]; [@bib26]; [@bib41]; [@bib40]). These observations suggest that *CCND1* might have an important role in the process of metastasis and the development of ECS.

On the other hand, the epidermal growth factor receptor gene (*EGFR*) is a transmembrane tyrosine kinase receptor. Signalling through this receptor leads to the activation of multiple signalling proteins that initiate a cascade of several signal pathways, including the Ras-Raf-mitogen-activated protein kinase pathway, the phosphatidylinositol 3-kinase-Akt pathway, and the signal transducer and activators of transcription pathway, all of which are potent oncogenic regulators of tumour cell growth, invasion, angiogenesis, and metastasis ([@bib4]; [@bib3]). Overexpression of *EGFR* is seen in approximately 80% of HNSCCs, and has been reported to be of strong prognostic value and to have a significant association with nodal metastasis ([@bib30]; [@bib45]; [@bib2]; [@bib5]; [@bib40]). However, EGFR overexpression is not always linked to the gene copy number aberrations ([@bib9]; [@bib13]). Thus, although our previous investigation revealed that copy number aberrations of this gene is one of the most significant prognostic markers in OSCCs ([@bib40]), it is not clear that the association between EGFR gene copy number status and the presence of ECS. In the present study, we therefore focused on copy number changes in these two genes in primary tumours.

There are two aims of the present study. The first is to confirm the clinical and prognostic significance of the presence of ECS in OSCCs. The second is to determine the factors significantly correlated with the presence of ECS. We examine a number of factors including clinicopathological features of the primary tumour, lymph node metastasis, and the *CCND1* and *EGFR* gene status of primary tumours, and evaluate the value of predicting the risk of ECS of metastatic lymph nodes.

Patients and methods
====================

Patient characteristics
-----------------------

The medical records of 127 consecutive OSCC patients who had undergone primary surgical excision with curative intent at the Maxillofacial Surgery, Graduate School, Tokyo Medical and Dental University (Tokyo, Japan), between June 1999 and April 2008, were reviewed for this study. No patients had preoperative treatment. All protocols of this study were reviewed and approved by the Research Ethics Committee of Tokyo Medical and Dental University. Informed consent was obtained from all patients in accordance with our Institutional guidelines. The clinical staging was defined on the basis of the International Union Against Cancer TNM classification ([@bib38]). The primary tumours were classified histopathologically as well-, moderately, or poorly differentiated according to the level of differentiation defined in the World Health Organization classification ([@bib44]). The mode of tumour invasion was also classified using a modification of the criteria of Jacobsson *et al* ([@bib19]; [@bib46]). Histological data obtained from neck dissection specimens included the number of positive nodes and the presence or absence of ECS. Extracapsular spread was defined as extension of the tumour through the capsule of the lymph node into the perinodal tissues. The presence of tumour cells in the capsule of the node was not considered ECS.

Fine-needle aspiration--fluorescence *in situ* hybridisation analysis
---------------------------------------------------------------------

To investigate the genetic status of the primary tumour, FISH analysis was performed. Samples were taken from 127 primary tumours by FNA technique, and FISH assays were performed as described previously using two types of BAC clone probes, specific for *CCND1* and *EGFR* (Vysis, Downers Grove, IL, USA), labelled with Spectrum Orange, and chromosome 11 and 7 centromeric DNA, labelled with Spectrum Green ([@bib23]). Samples were grouped as follows: balanced disomy, chromosome/nucleus ratio (C/N) ⩽2.5; balanced trisomy, C/N 26--3.0; balanced polysomy, C/N \>3.0 (in which balanced patterns had an average ratio gene/chromosome copy number per nucleus (G/C) of 0.9--1.2); and amplification, G/C \>1.2 and gene/nucleus ratio \>3.0 ([@bib39]; [@bib40]). Tumours showing disomy were considered normal, with all other tumours being considered to have gene numerical aberrations.

Statistical analysis
--------------------

Disease-free survival (DFS) and OS rates were estimated using the Kaplan--Meier method and statistical significance was determined using the log-rank test. Disease-free survival time was defined as the interval between the date of first visit and the date of the development of local, regional recurrence, and distant metastasis after surgery. Overall survival time was also calculated from the date of initial examination to the date of death, or to the date of the 5-year follow-up. Multivariate DFS and OS analyses were performed using the Cox proportional hazards model. Multivariate analysis for ECS risk factors was performed using the logistic regression analysis. The level of significance was set at *P*\<0.05. All statistical analyses were performed using SPSS for Windows (version 17.0, SPSS, Inc., Chicago, IL, USA).

Results
=======

Demographic data
----------------

A total of 127 patients (86 men (67. 7%); mean age 60.2 years; age range 20--89 years) were included in this study. The median follow-up period was 43.2 months (range 6.0--60 months).

Tumour characteristics and staging
----------------------------------

The sites of the primary tumours were derived from tongue (*n*=77), lower gingiva (*n*=27), floor of the mouth (*n*=10), upper gingiva (*n*=4), and the buccal mucosa (*n*=9). A total of 41 of the 127 patients (32.3%) had T1 tumours, 61 (48.0%) had T2 tumours, 12 (9.5%) had T3 tumours, and 13 (10.2%) had T4 tumours at the time of presentation. The growth pattern of the primary tumour was classified as superficial (*n*=27), exophytic (*n*=43), and endophytic (*n*=57). A total of 74 of the 127 patients (58.3%) had a N0 node, 21 (16.5%) patients had a pathologically positive node without ECS (pN+/ECS−), and 32 (25.2%) patients had a pathologically positive node with ECS (pN+/ECS+).

Impact of extracapsular spread on survival
------------------------------------------

To assess the impact of ECS on survival, the survival data of the patients were compared between the three groups, N0, pN+/ECS−, and pN+/ECS+. Kaplan--Meier survival curves for DFS and OS are presented in [Figures 1A and B](#fig1){ref-type="fig"}, respectively. Disease-free survival rates for 5 years are 86.5% for N0, 90.5% for pN+/ECS−, and 40.1% for pN+/ECS+ patients. Overall survival rates for 5 years are 89.1% for N0, 90.2% for pN+/ECS−, and 45.1% for pN+/ECS+ patients. These results clearly demonstrate the adverse impact of group pN+/ECS+ compared with groups N0 and pN+/ECS− on both disease recurrence (log-rank test. *P*\<0.0001 and *P*\<0.0001) and OS (log-rank test. *P*\<0.0001 and *P*=0.001). Multivariate Cox proportional hazards analysis revealed that smoking habit, pathological T stage, cellular differentiation, and presence of ECS were independently significant in predicting DFS ([Table 1](#tbl1){ref-type="table"}). With regard to OS, the pathological T stage and presence of ECS retained a statistically significant prognostic value ([Table 1](#tbl1){ref-type="table"}). Therefore, pathological T stage and presence of ECS are significant independent predictors in both DFS and OS.

Associations with extracapsular spread
--------------------------------------

The correlations between presence of ECS and clinicopathological parameters in the OSCC patients are summarised in [Table 2](#tbl2){ref-type="table"}. There were no significant associations between presence of ECS and age, smoking habit, tumour site, growth pattern, pathological T stage, and cellular differentiation. In contrast, the presence of ECS was significantly correlated with the number of pathologically positive nodes (*P*=0.001), indicating that ECS is more frequent in patients with multiple positive nodes. With regard to the size of the metastatic lymph node, although the presence of ECS occurred more frequently in large nodes at both the minor and major axis compared with small metastatic lymph nodes, these differences were not statistically significant. On the other hand, the presence of *CCND1* and *EGFR* numerical aberrations of the primary tumour was significantly associated with the presence of ECS in metastatic lymph nodes (*P*=0.011 and 0.004, respectively). A multivariate logistic regression analysis, including clinicopathological factors, lymph node metastasis, and genetic status of the primary tumour, revealed that only the number of pathologically positive lymph nodes and the presence of *EGFR* numerical aberrations of the primary tumour were significantly independent predictors of ECS (odds ratio=9.400 and 8.206, 95% confidence interval=2.136--41.370, and 1.631--41.295, *P*=0.003 and *P*=0.011, respectively, hit ratio=73.1% [Table 3](#tbl3){ref-type="table"}).

Discussion
==========

For HNSCCs, including oral cancer, ECS has been shown to be a significant predictor of treatment outcome. [@bib25] reviewed 266 patients with SCC of the tongue and determined a 5-year disease-specific survival rate of 88% for pN0 patients, 65% for patients with intranodal lymph node metastases, and 48% for patients with extranodal lymph node metastases. [@bib42] also showed that OSCC patients with no positive nodes or positive nodes without ECS had nearly the same 5-year rates for being free from distant metastases (79, 82%), local recurrence (61, 67%), neck recurrence (84, 87%), and survival (67, 59%), whereas those with ECS had 1.5--2 times worse rates for every clinical parameter. [@bib35] reported a 5-year disease-specific survival rate of 40% with and 72% without ECS for patients with oral cancer. In the current study, we also clearly demonstrated the adverse impact of group pN+/ECS+ compared with groups N0 and pN+/ECS− on both disease recurrence and OS. Moreover, multivariate Cox proportional hazard analysis revealed that pathological T stage and presence of ECS is significantly correlated with disease recurrence and survival. These findings are in keeping with the previous observations that ECS is a discriminatory and significant predictor for prognosis of patients with HNSCCs ([@bib27]; [@bib28]; [@bib35]; [@bib25]; [@bib16]; [@bib43]; [@bib42]; [@bib21]).

Of first interest in this study was that multivariate analysis indicated the presence of ECS rather than the existence of a metastatic lymph node as a significant predictor of disease recurrence and poor prognosis. Rather than indicating the difference between N0 and N+, these findings show that differentiation between intra- and extra-capsular spread of the lymph node contains the essential discriminatory power. Recently, [@bib33] reviewed 400 OSCC patients, and reported a 5-year OS rate in ECS-positive patients of 23% compared with 52% in pN+/ECS− patients and with 65% in pN0 patients. They also found differences in survival curves to be highly significant between pN0, pN+/ECS−, and pN+/ECS+ (*P*\<0.001, log-rank test). These findings are in accord with our results, indicating that the presence of ECS is a more significant predictor of recurrence and survival than the presence of cervical lymph node metastasis.

However, at present, the existence of ECS can only be clarified after neck surgery, thus preventing preoperative determination. Moreover, as a significant number of ECS are detected in early-nodal disease and even in patients with N0 neck, recent imaging modalities are unable to detect ECS before surgery ([@bib1]; [@bib12]; [@bib10]; [@bib31]). Therefore, it is necessary to determine the predictive markers that indicate a high risk of ECS. Thus, in this study, we attempted to determine significant factors related to ECS: multivariate logistic regression analysis revealed that number of pathologically positive lymph nodes and presence of *EGFR* numerical aberrations of the primary tumour were significantly independent predictors.

ECS is histopathologically documented in approximately 60% of patients with cervical metastases, and is generally thought to be related to nodal size ([@bib10]). However, although ECS has been detected in 60--100% of lymph nodes \>3 cm in diameter, it has also been shown in 39--59% of nodes \<3 cm and in 23% of nodes \<1 cm ([@bib29]). Moreover, ECS has been determined in patients with N0 neck, whereas the incident rate of ECS in those with N0 neck is between 13 and 60% ([@bib11]). In this study, we investigated the association between presence of ECS and metastatic lymph node size, and determined that although ECS occurs more frequently in larger-sized nodes, in both the minor and major axis, compared with small nodes; but these differences were not statistically significant. This finding is compatible with the previous observations ([@bib11]; [@bib29]). Taken together, these findings suggest that ECS can occur in several ways. [@bib29] recently speculated that in larger nodes, mechanical disruption, as a result of an expanding tumour mass, is the main cause of ECS. On the other hand, in smaller nodes, ECS might result from tumour emboli, lodged in the capsular sinuses, or by focal destruction of capsular collagen by collagenase produced by the tumour cells. However, these processes remain to be elucidated, and further investigation is warranted.

Several reports have documented the clinicopathological factors significantly correlated with ECS. Recently, [@bib18] retrospectively studied 186 patients with laryngeal and hypopharyngeal cancer and, using multivariate analysis, documented that only number of (\>3) lymph node metastases was a significant independent predictor of ECS. More recently, also by means of multivariate analysis, [@bib33] examined 400 patients with OSCCs and demonstrated that age \>75 years, smoking, and heavy use of alcohol were independent predictors of ECS. Furthermore, [@bib43], using univariate analysis, investigated 173 OSCC patients and found that many clinicopathological parameters, including gender, age, status of the resection margin, number of positive nodes, largest metastatic deposit, highest anatomical level of involvement, and pathological N stage, were significantly correlated with ECS. In the present study, we retrospectively examined 127 patients with OSCCs and multivariate analysis revealed that number of pathologically positive lymph nodes and presence of *EGFR* numerical aberrations at the primary tumours were significantly associated with ECS. The number of positive lymph nodes was shown to have a correlation in the abovementioned reports, suggesting it can be used in the prediction of ECS. However, the number of pathologically positive nodes is determined after surgery, and it is therefore impracticable to obtain this information preoperatively. Therefore, it is not useful for preoperative selection of patients at high risk of ECS.

On the contrary, second but most interesting and important finding of this study was that ECS in the metastatic lymph node is significantly associated with *EGFR* numerical aberrations at the primary tumours. This finding suggests that patients at high risk of ECS could be preoperatively determined by examining *EGFR* copy number changes in primary tumours by means of FISH. Although there are several reports ([@bib8]; [@bib47]; [@bib17]) that showed the protein or mRNA overexpression of EGFR significantly correlated with ECS in the OSCCs, this is the first study investigating the association between EGFR gene copy number at the primary tumour and the presence of ECS in the metastatic lymph node, and clearly demonstrating the significant correlation between them. Generally, the association between EGFR FISH status and protein or mRNA expression level still remains to be concluded ([@bib9]; [@bib13]). Thus, EGFR gene copy number aberrations have not always linked to overxepression of this mRNA or protein. Therefore, at present, the significant association between *EGFR* FISH status and ECS might not be related with *EGFR* alone. FISH-positive status may be a surrogate marker of generalised genetic instability in the tumour or of additional genes that are co-amplified with EGFR. However, how these mechanisms contribute to the occurrence of ECS remains unclear. Further investigations are required.

In conclusion, the present study clearly demonstrated that ESC is an independent prognostic factor of OSCCs. Moreover, number of pathologically positive lymph nodes and *EGFR* numerical aberrations of the primary tumours were also shown to be excellent predictors of ECS in OSCCs. Especially, copy number changes of the *EGFR* in the primary tumours were indicated as clinically useful for selection of patients at high risk of ECS who would benefit from targeted aggressive multimodality therapy.

![(**A**) Kaplan--Meier curve for disease-free survival according to lymph node status. (**B**) Kaplan--Meier curve for overall survival according to lymph node status.](bjc201122f1){#fig1}

###### Independent prognosis factors in multivariate Cox proportional hazards analysis

                                  **Disease-free survival**   **Overall survival**                                   
  ------------------------------ --------------------------- ---------------------- --------------- -------- ------- ---------------
  Age                                        NS                       ---                 ---          NS      ---         ---
  Gender                                     NS                       ---                 ---          NS      ---         ---
  Alcohol habit                              NS                       ---                 ---          NS      ---         ---
  Smoking habit                            0.0070                    3.365           1.387--8.165      NS      ---         ---
  Pathological T stage                     0.0001                    5.505           2.417--12.540   0.0001   4.574   2.006--10.429
  Cellular differentiation                 0.0380                    2.448           1.051--5.701      NS      ---         ---
  Mode of invasion                           NS                       ---                 ---          NS      ---         ---
  pN                                         NS                       ---                 ---          NS      ---         ---
  ECS                                      0.0001                    7.345           3.269--16.501   0.0001   5.986   2.460--14.566
  *CCND1* numerical aberration               NS                       ---                 ---          NS      ---         ---
  *EGFR* numerical aberration                NS                       ---                 ---          NS      ---         ---

Abbreviations: CI=confidence interval; ECS=extracapsular spread; *EGFR*=epidermal growth factor receptor gene; HR=hazard ratio; NS=not significant; pN=pathologically positive node.

###### Univariate analysis of potential predictors of ECS

  **Clinicopathologic parameters**                             ***N*−\***   **pN+ ECS−\*\***   **pN+ ECS+\*\*\***   ***P*-value[a](#t2-fn2){ref-type="fn"}**
  ------------------------------------------------------------ ------------ ------------------ -------------------- ------------------------------------------
  *Gender*                                                                                                          
   Male                                                        45           14                 27                   0.023[b](#t2-fn3){ref-type="fn"}
   Female                                                      29           7                  5                     
  *Age (years)*                                                                                                     
   ⩽60                                                         35           10                 15                   NS
   \>60                                                        39           11                 17                    
  *Alcohol habit*                                                                                                   
   (−)                                                         38           8                  10                   0.005[b](#t2-fn3){ref-type="fn"}
   (+)                                                         33           13                 21                    
  *Smoking habit*                                                                                                   
   (−)                                                         39           12                 11                   NS
   (+)                                                         32           9                  20                    
  *Tumor site*                                                                                                      
   Tongue                                                      45           13                 19                   NS
   Lower gingiva                                               18           4                  5                     
   Floor of mouth                                              3            2                  5                     
   Upper gingiva                                               2            1                  1                     
   Buccal mucosa                                               6            1                  2                     
  *Growth pattern*                                                                                                  
   Superficial                                                 18           3                  6                    NS
   Exophytic                                                   28           8                  7                     
   Endophytic                                                  28           10                 19                    
  *Pathological T stage*                                                                                            
   1--2                                                        65           14                 23                   0.042[c](#t2-fn4){ref-type="fn"}
   3--4                                                        9            7                  9                     
  *Cellular differentiation*                                                                                        
   Well/moderate                                               64           19                 24                   NS
   Poor                                                        10           2                  8                     
  *Mode of invasion*                                                                                                
   1--3                                                        53           13                 14                   0.009[b](#t2-fn3){ref-type="fn"}
   4C--D                                                       21           8                  18                    
  *Number of positive nodes*[d](#t2-fn5){ref-type="fn"}                                                             
   1                                                           ---          13                 5                    0.001[e](#t2-fn6){ref-type="fn"}
   ⩾2                                                          ---          8                  27                    
  *Size of positive nodes*[f](#t2-fn7){ref-type="fn"} *(mm)*                                                        
   Minor axis (3--20)                                                                                                
    ⩽10                                                        ---          13                 16                   NS
    \>10                                                       ---          8                  16                    
   Major axis (5--27)                                                                                                
    ⩽14                                                        ---          14                 14                   NS
    \>14                                                       ---          7                  18                    
  *Gene status in primary tumor*                                                                                    
   *CCND1* numerical aberration                                                                                     
    (−)                                                        56           16                 12                   0.0001[b](#t2-fn3){ref-type="fn"}
    (+)                                                        18           5                  20                   0.011[e](#t2-fn6){ref-type="fn"}
   *EGFR* numerical aberration                                                                                      
    (−)                                                        51           18                 14                   0.018[b](#t2-fn3){ref-type="fn"}
    (+)                                                        23           3                  18                   0.004[e](#t2-fn6){ref-type="fn"}

Abbreviations: ECS=extracapsular spread; *EGFR*=epidermal growth factor receptor gene; NS=not significant.

The *P*-value was determined using the two-tailed Fisher exact test.
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Determined according to histopathological diagnosis.

^\*\*^ *vs* ^\*\*\*^.

Detected by computed tomography.

###### Independent predictors of ECS in multivariate logistic regression analysis

  **Variables**                   **OR**    **95% CI**     ***P*-value**
  ------------------------------ -------- --------------- ---------------
  Age                              ---          ---             NS
  Gender                           ---          ---             NS
  Alcohol habit                    ---          ---             NS
  Smoking habit                    ---          ---             NS
  Pathological T stage             ---          ---             NS
  Cellular differentiation         ---          ---             NS
  Mode of invasion                 ---          ---             NS
  Number of positive nodes        9.400    2.136--41.370       0.003
  *CCND1* numerical aberration     ---          ---             NS
  *EGFR* numerical aberration     8.206    1.631--41.295       0.011

Abbreviations: CI=confidence interval; ECS=extracapsular spread; NS=not significant; OR=odds ratio.
